scholarly journals Long‐term safety and tolerability of lacosamide monotherapy in patients with epilepsy: Results from a multicenter, open‐label trial

2021 ◽  
Author(s):  
Elinor Ben‐Menachem ◽  
Jacqueline Dominguez ◽  
József Szász ◽  
Cynthia Beller ◽  
Charles Howerton ◽  
...  
Keyword(s):  
Open Label ◽  
Open Label Trial ◽  
Patients With Epilepsy

scholarly journals Long-Term Evaluation of Sinemet® CR in Parkinsonian Patients with Motor Fluctuations

1991 ◽  
Vol 18 (4) ◽  
pp. 467-471 ◽  
Author(s):  
J. Thomas Hutton ◽  
Jerry L. Morris
Keyword(s):  
Term Treatment ◽  
Motor Fluctuations ◽  
Open Label ◽  
Release Formulation ◽  
Long Term Treatment ◽  
Dosing Frequency ◽  
Efficacy Measures ◽  
Term Evaluation ◽  
Open Label Trial

ABSTRACT:The safety and efficacy of Sinemet® CR, a controlled-release formulation of carbidopa/levodopa, were investigated in a three year, open-label trial involving 18 parkinsonian patients with fluctuating motor response. The average daily levodopa dosing frequency did not change significantly during long-term treatment. Efficacy measures generally revealed a gradual progression of parkinsonian disability. Patient diaries of motor fluctuations revealed relative stability of time “on” but with a tendency toward increased time “on with dyskinesias” over the 36 month followup period. There were no adverse laboratory results deemed to be related to Sinemet® CR and no unexpected side effects were observed.

Immunogenicity of a Standard Trivalent Influenza Vaccine in Patients on Long-term Hemodialysis: An Open-Label Trial

2009 ◽  
Vol 54 (1) ◽  
pp. 77-85 ◽  
Author(s):  
Johan Scharpé ◽  
Willy E. Peetermans ◽  
Johan Vanwalleghem ◽  
Bart Maes ◽  
Bert Bammens ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Open Label ◽  
Trivalent Influenza Vaccine ◽  
Open Label Trial
Sign in / Sign up

Export Citation Format

Share Document